Cargando…

Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies

PURPOSE: To investigate the experiences of adults living with chronic myeloid leukaemia and treated with tyrosine kinase inhibitors, with particular reference to factors influencing adherence. METHODS: A thematic synthesis of all published qualitative studies examining adults with chronic myeloid le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hewison, Ann, Atkin, Karl, McCaughan, Dorothy, Roman, Eve, Smith, Alex, Smith, Graeme, Howell, Debra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Churchill Livingstone 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167512/ https://www.ncbi.nlm.nih.gov/pubmed/32169687 http://dx.doi.org/10.1016/j.ejon.2020.101730

Ejemplares similares

Experiences and preferences for psychosocial support: a qualitative study exploring the views of patients with chronic haematological cancers
por: Sheridan, Rebecca, et al.
Publicado: (2023)

Treatment decision making (TDM): a qualitative study exploring the perspectives of patients with chronic haematological cancers
por: McCaughan, Dorothy, et al.
Publicado: (2022)

Incurable but treatable: Understanding, uncertainty and impact in chronic blood cancers—A qualitative study from the UK’s Haematological Malignancy Research Network
por: Howell, Debra A., et al.
Publicado: (2022)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

Determinants of hospital death in haematological cancers: findings from a qualitative study
por: McCaughan, Dorothy, et al.
Publicado: (2018)

Palliative care specialists’ perceptions concerning referral of haematology patients to their services: findings from a qualitative study
por: McCaughan, Dorothy, et al.
Publicado: (2018)

Haematology nurses' perspectives of their patients' places of care and death: A UK qualitative interview study
por: McCaughan, Dorothy, et al.
Publicado: (2019)

Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study
por: McCaughan, Dorothy, et al.
Publicado: (2019)

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
por: Lindström, H. Jonathan G., et al.
Publicado: (2019)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
por: Allegra, Sarah, et al.
Publicado: (2023)

Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma
por: Howell, Debra A, et al.
Publicado: (2015)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia
por: Crisan, AM, et al.
Publicado: (2015)

Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells
por: Pearson, Stella, et al.
Publicado: (2022)

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
por: Nishiyama-Fujita, Yuriko, et al.
Publicado: (2022)

Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network
por: Howell, Debra A, et al.
Publicado: (2013)

Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment
por: Trivedi, Digisha, et al.
Publicado: (2014)

Why are patients with chronic myeloid leukaemia (non-)adherent?
por: Abraham, I, et al.
Publicado: (2012)

Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
por: Kekäle, Meri, et al.
Publicado: (2014)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)

COVID-19 in patients with chronic myeloid leukaemia on tyrosine kinase inhibitor therapy: a Honduran observational study
por: Fajardoa, Carlos J, et al.
Publicado: (2022)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol
por: Balakumaran, Janatani, et al.
Publicado: (2019)

Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases
por: Gu, Ruixin, et al.
Publicado: (2022)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis
por: Voisset, Edwige, et al.
Publicado: (2020)

Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan
por: Tsai, Yu-Fen, et al.
Publicado: (2018)

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
por: Shi, Ping, et al.
Publicado: (2010)

Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors
por: Piekarska, Agnieszka, et al.
Publicado: (2016)

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
por: Chen, Li-Chia, et al.
Publicado: (2013)

Excess morbidity and mortality among survivors of childhood acute lymphoblastic leukaemia: 25 years of follow-up from the United Kingdom Childhood Cancer Study (UKCCS) population-based matched cohort
por: Kane, Eleanor, et al.
Publicado: (2022)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
por: Tan, Bee Kim, et al.
Publicado: (2021)

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
por: Shallis, Rory M., et al.
Publicado: (2023)

Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
por: McMullan, RR, et al.
Publicado: (2019)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

S158: EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA
por: LI, Zongru, et al.
Publicado: (2023)

PB1978: PATIENT-CENTREDNESS IS PIVOTAL IN A PROSPECTIVE DOSE REDUCTION TRIAL OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
por: Djodikromo, Melissa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1lav3rfqvq3gsphhea9kad4f1l